Literature DB >> 19754790

Chemotherapy during pregnancy: a review of the literature.

K Autio1, K M Rassnick, S J Bedford-Guaus.   

Abstract

Although diagnosing cancer during pregnancy is uncommon in veterinary medicine, when it occurs, chemotherapy may represent a reasonable treatment option. A major consideration is that physiological changes associated with pregnancy affect drug pharmacokinetics and complicate correct dosing of chemotherapy agents. Additionally, most antineoplastic drugs are able to cross the placenta thus adversely affecting the foetus. However, favourable outcomes have been observed in human beings when chemotherapy has been administered after organogenesis. Conversely, chemotherapy should be avoided during the early embryonic and organogenesis periods as it might lead to foetal death and/or major malformations.

Entities:  

Year:  2007        PMID: 19754790     DOI: 10.1111/j.1476-5829.2006.00119.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  3 in total

1.  Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991-2017).

Authors:  Daniela Luethy; Angela E Frimberger; Daniela Bedenice; Barbara S Byrne; Erin S Groover; Rachel B Gardner; Trisha Lewis; Valerie S MacDonald; Lauren Proctor-Brown; Joy E Tomlinson; Kenneth M Rassnick; Amy L Johnson
Journal:  J Vet Intern Med       Date:  2019-01-12       Impact factor: 3.333

2.  Protective role of Codiaeum variegatum against genotoxicity induced by carmustine in somatic and germ cells of male mice.

Authors:  Maha A Fahmy; Ayman A Farghaly; Entesar E Hassan; Zeinab M Hassan; Howaida I Abd-Alla
Journal:  Mol Biol Rep       Date:  2022-09-02       Impact factor: 2.742

3.  ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics in veterinary practice.

Authors:  Annette N Smith; Shawna Klahn; Brenda Phillips; Lisa Parshley; Peter Bennett; Andi Flory; Rosemary Calderon
Journal:  J Vet Intern Med       Date:  2018-03-30       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.